RVMD — Revolution Medicines Income Statement
0.000.00%
Last trade - 00:00- $7.56bn
- $5.46bn
- 40
- 23
- 27
- 20
Annual income statement for Revolution Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 43 | 29.4 | 35.4 | 11.6 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 154 | 217 | 294 | 499 | 690 |
| Operating Profit | -111 | -188 | -258 | -487 | -690 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -109 | -187 | -249 | -440 | -601 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -108 | -187 | -249 | -436 | -600 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -108 | -187 | -249 | -436 | -600 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -110 | -187 | -249 | -436 | -600 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 |